Celyad Oncology SA (CYAD)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 20, 2025

$0.53

P/E Ratio

N/A

Market Cap

$22.19M

Jan 29, 2024Mar 1, 2024Apr 5, 2024May 9, 2024Jun 13, 2024Jul 17, 2024Aug 20, 2024Sep 25, 2024Oct 30, 2024Dec 3, 2024Jan 20, 2025$0.00$10.00
  • ONT
Description

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Metrics

Overview

  • HQMont-Saint-Guibert, WA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerCYAD
  • Price$0.526679-1.69%

Trading Information

  • Market cap$22.19M
  • Float93.95%
  • Average Daily Volume (1m)33,170
  • Average Daily Volume (3m)92,911
  • EPS-$0.33

Company

  • Revenue$0.10M
  • Rev growth (1yr)N/A
  • Net incomeN/A
  • Gross marginN/A
  • EBITDA margin-9,610.78%
  • EBITDAN/A
  • EVN/A
  • EV/Revenue203.10
  • P/EN/A
  • P/S294.03
  • P/B6.48
Documents